161 related articles for article (PubMed ID: 28674022)
1. FSIP1 binds HER2 directly to regulate breast cancer growth and invasiveness.
Liu T; Zhang H; Sun L; Zhao D; Liu P; Yan M; Zaidi N; Izadmehr S; Gupta A; Abu-Amer W; Luo M; Yang J; Ou X; Wang Y; Bai X; Wang Y; New MI; Zaidi M; Yuen T; Liu C
Proc Natl Acad Sci U S A; 2017 Jul; 114(29):7683-7688. PubMed ID: 28674022
[TBL] [Abstract][Full Text] [Related]
2. Over-expression of FSIP1 promotes breast cancer progression and confers resistance to docetaxel via MRP1 stabilization.
Yan M; Wang J; Ren Y; Li L; He W; Zhang Y; Liu T; Li Z
Cell Death Dis; 2019 Feb; 10(3):204. PubMed ID: 30814489
[TBL] [Abstract][Full Text] [Related]
3. FSIP1 regulates autophagy in breast cancer.
Liu C; Sun L; Yang J; Liu T; Yang Y; Kim SM; Ou X; Wang Y; Sun L; Zaidi M; New MI; Yuen T; Guo Q
Proc Natl Acad Sci U S A; 2018 Dec; 115(51):13075-13080. PubMed ID: 30509973
[TBL] [Abstract][Full Text] [Related]
4. FSIP1 is correlated with estrogen receptor status and poor prognosis.
Li X; Song X; Ma J; Zhao Y; Jiang Q; Zhao Z; Li M
Mol Carcinog; 2020 Jan; 59(1):126-135. PubMed ID: 31713931
[TBL] [Abstract][Full Text] [Related]
5. Elevated expression of cancer/testis antigen FSIP1 in ER-positive breast tumors.
Chapman KB; Prendes MJ; Kidd JL; Sternberg H; West MD; Wagner J
Biomark Med; 2013 Aug; 7(4):601-11. PubMed ID: 23905897
[TBL] [Abstract][Full Text] [Related]
6. Recombinant viral protein VP1 suppresses HER-2 expression and migration/metastasis of breast cancer.
Hung SW; Chiu CF; Chen TA; Chu CL; Huang CC; Shyur LF; Liang CM; Liang SM
Breast Cancer Res Treat; 2012 Nov; 136(1):89-105. PubMed ID: 22983836
[TBL] [Abstract][Full Text] [Related]
7. CD147 knockdown improves the antitumor efficacy of trastuzumab in HER2-positive breast cancer cells.
Xiong L; Ding L; Ning H; Wu C; Fu K; Wang Y; Zhang Y; Liu Y; Zhou L
Oncotarget; 2016 Sep; 7(36):57737-57751. PubMed ID: 27363028
[TBL] [Abstract][Full Text] [Related]
8. Expression and clinicopathological significance of FSIP1 in breast cancer.
Zhang H; Luo M; Jin Z; Wang D; Sun M; Zhao X; Zhao Z; Lei H; Li M; Liu C
Oncotarget; 2015 Apr; 6(12):10658-66. PubMed ID: 25826084
[TBL] [Abstract][Full Text] [Related]
9. FSIP1 enhances the therapeutic sensitivity to CDK4/6 inhibitors in triple-negative breast cancer patients by activating the Nanog pathway.
Chen G; Sun L; Gu X; Ai L; Yang J; Zhang Z; Hou P; Wang Y; Ou X; Jiang X; Qiao X; Ma Q; Niu N; Xue J; Zhang H; Yang Y; Liu C
Sci China Life Sci; 2023 Dec; 66(12):2805-2817. PubMed ID: 37460715
[TBL] [Abstract][Full Text] [Related]
10. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
[TBL] [Abstract][Full Text] [Related]
11. HR+HER2- breast cancers with growth factor receptor-mediated EMT have a poor prognosis and lapatinib downregulates EMT in MCF-7 cells.
Desai K; Aiyappa R; Prabhu JS; Nair MG; Lawrence PV; Korlimarla A; Ce A; Alexander A; Kaluve RS; Manjunath S; Correa M; Srinath BS; Patil S; Kalamdani A; Prasad M; Sridhar TS
Tumour Biol; 2017 Mar; 39(3):1010428317695028. PubMed ID: 28349782
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu.
Piechocki MP; Yoo GH; Dibbley SK; Lonardo F
Cancer Res; 2007 Jul; 67(14):6825-43. PubMed ID: 17638894
[TBL] [Abstract][Full Text] [Related]
13. Fucoidan induces changes in the epithelial to mesenchymal transition and decreases metastasis by enhancing ubiquitin-dependent TGFβ receptor degradation in breast cancer.
Hsu HY; Lin TY; Hwang PA; Tseng LM; Chen RH; Tsao SM; Hsu J
Carcinogenesis; 2013 Apr; 34(4):874-84. PubMed ID: 23275155
[TBL] [Abstract][Full Text] [Related]
14. Brk/PTK6 cooperates with HER2 and Src in regulating breast cancer cell survival and epithelial-to-mesenchymal transition.
Ai M; Liang K; Lu Y; Qiu S; Fan Z
Cancer Biol Ther; 2013 Mar; 14(3):237-45. PubMed ID: 23291984
[TBL] [Abstract][Full Text] [Related]
15. The miR-644a/CTBP1/p53 axis suppresses drug resistance by simultaneous inhibition of cell survival and epithelial-mesenchymal transition in breast cancer.
Raza U; Saatci Ö; Uhlmann S; Ansari SA; Eyüpoğlu E; Yurdusev E; Mutlu M; Ersan PG; Altundağ MK; Zhang JD; Doğan HT; Güler G; Şahin Ö
Oncotarget; 2016 Aug; 7(31):49859-49877. PubMed ID: 27409664
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of β-catenin decreases the tumorigenicity, but promotes epithelial-mesenchymal transition in breast cancer cells.
Cai K; Jiang L; Wang J; Zhang H; Wang X; Cheng D; Dou J
J Cancer Res Ther; 2014; 10(4):1063-70. PubMed ID: 25579555
[TBL] [Abstract][Full Text] [Related]
17. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
[TBL] [Abstract][Full Text] [Related]
18. The dual role of FOXF2 in regulation of DNA replication and the epithelial-mesenchymal transition in breast cancer progression.
Lo PK; Lee JS; Liang X; Sukumar S
Cell Signal; 2016 Oct; 28(10):1502-19. PubMed ID: 27377963
[TBL] [Abstract][Full Text] [Related]
19. Long noncoding RNA SNHG15 promotes human breast cancer proliferation, migration and invasion by sponging miR-211-3p.
Kong Q; Qiu M
Biochem Biophys Res Commun; 2018 Jan; 495(2):1594-1600. PubMed ID: 29217194
[TBL] [Abstract][Full Text] [Related]
20. Leptin promotes epithelial-mesenchymal transition of breast cancer via the upregulation of pyruvate kinase M2.
Wei L; Li K; Pang X; Guo B; Su M; Huang Y; Wang N; Ji F; Zhong C; Yang J; Zhang Z; Jiang Y; Liu Y; Chen T
J Exp Clin Cancer Res; 2016 Oct; 35(1):166. PubMed ID: 27769315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
